Showing 1341-1350 of 1560 results for "".
- Johnson & Johnson Vision Introduces Contact Lens with Transitions Light Intelligent Technologyhttps://modernod.com/news/johnson-johnson-vision-announces-contact-lens-innovation-with-acuvue-oasys-with-transitions-light-intelligent-technology/2480264/Johnson & Johnson Vision has introduced the Acuvue Oasys with Transitions Light Intelligent Technology, a first-of-its-kind contact lens that provides wearers with vision correction and a dynamic photochromic filter that helps to continuously balance the amount of light entering the eye, acco
- Monica Jong, PhD, Appointed Global Professional Education Lead, Myopia at Johnson & Johnson Visionhttps://modernod.com/news/monica-jong-phd-appointed-global-professional-education-lead-myopia-at-johnson-johnson-vision/2480309/Monica Jong, PhD, co-founder of the
- Johnson & Johnson Vision Receives FDA Clearance for Catalys cOS 6.0 Software for Astigmatism Managementhttps://modernod.com/news/johnson-johnson-vision-recevies-fda-clearance-for-catalys-cos-6-0-software-for-astigmatism-management/2477915/The FDA has granted 510(k) clearance for new software for the Catalys Precision Laser System that aims to simplify astigmatism management workflow and increase operational efficiency. The Catalys cOS 6.0 software with advanced astigmatism management is a collaboration with Cassini Technolog
- Johnson & Johnson Vision Ceases Customer-Facing Operations for Sightbox Online Contact Lens Subscription Servicehttps://modernod.com/news/johnson-johnson-vision-ceases-customer-facing-operations-for-sightbox-online-contact-lens-subscription-service/2477054/
- J&J to Present New Data Demonstrating Superiority of Acuvue Oasys Max 1-Day for Astigmatism at AAOpthttps://modernod.com/news/jj-to-present-new-data-demonstrating-superiority-of-acuvue-oasys-max-1-day-for-astigmatism-at-aaopt/2484158/Johnson & Johnson announced new clinical data demonstrating significantly higher end-of-day comfort and stronger overall patient preference for the Acuvue Oasys Max 1-Day for Astigmatism contact lenses compared to Dailies Total1 for Astigmatism.
- J&J Launches Daily Disposable Multifocal Toric Contact Lens: Acuvue Oasys Max 1-Day Multifocal for Astigmatismhttps://modernod.com/news/johnson-johnson-launches-daily-disposable-multifocal-toric-contact-lens-acuvue-oasys-max-1-day-multifocal-for-astigmatism/2482858/Johnson & Johnson announced the launch of Acuvue Oasys Max 1-Day Multifocal for Astigmatism, a daily disposable contact lens for people with both astigmatism and presbyopia. The company says this contact lens provides patients crisp, clear, stable vision at all distances and in all
- TECLens Secures $9.3 Million Series A Funding to Advance Its Noninvasive Refractive Technologyhttps://modernod.com/news/teclens-secures-93-million-series-a-funding-to-advance-its-noninvasive-refractive-technology/2482658/TECLens announced it raised $9.3 million in a Series A round to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. The funding round was co-led by Johnson &
- J&J's Nipocalimab Significantly Improves Sjögren’s Disease Activity in a Phase 2 Studyhttps://modernod.com/news/jjs-nipocalimab-significantly-improves-sjogrens-disease-activity-in-a-phase-2-study/2482323/Johnson & Johnson announced that patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the phase 2 DAHLIAS dose-rang
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Tilak Healthcare Raises €10 Million to Continue Growing Its Ophthalmological Telemedicine Offeringhttps://modernod.com/news/tilak-healthcare-raises-eur10-million-to-continue-growing-its-leading-ophthalmological-telemedicine-offering/2481890/Tilak Healthcare has raised €10 million in a funding to accelerate the roll-out of OdySight in France and abroad, and to develop new solutions for other medical conditions. OdySight is the first remote monitoring system for ophthalmic conditions combined with a gaming interface designed